| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 31.01.2008 (6053
dage). |
Ingen historik.
| Branche | | Ventureselskaber og kapitalfonde (643040). |
| Sidst opdateret den 09.12.2017 og
angivet som gældende fra 07.02.2008 (6046
dage). |
| Historik | Start | Stop |
|---|
| Ventureselskaber og kapitalfonde (643040) | 07.02.2008 | |
| Udlejning af erhvervsejendomme (682040) | 31.01.2008 | 06.02.2008 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 11.03.2015 og
angivet som gældende fra 31.01.2008 (6053
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | NORDIC BIOTECH OPPORTUNITY FUND K/S. |
| Sidst opdateret den 12.03.2015 og
angivet som gældende fra 07.02.2008 (6046
dage). |
Ingen historik.
| Tegningsregel | | Virksomheden tegnes af komplementaren. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 27.05.2014 (3745
dage). |
| Fortolkning
(1 tegningsmulighed)
| | komplementaren |
Ingen historik.
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements
applicable in Denmark. Our responsibilities under those standards and requirements are further
described in the "Auditor’s responsibilities for the audit of the financial statements" section of this auditor’s
report. We are independent of the Entity in accordance with the International Ethics Standards Board for
Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical
requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with
these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
for our opinion.
Konklusion (revision):We have audited the financial statements of Nordic Biotech Opportunity Fund K/S for the financial year 01. 01. 2023 -
31. 12. 2023, which comprise the income statement, balance sheet, statement of changes in equity and
notes, including a
summary of significant accounting policies. The financial statements are prepared in
accordance with the
Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31. 12. 2023 and of the results of its operations for the financial year 01. 01. 2023 - 31. 12. 2023 in accordance
with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the management commentary.
Our opinion on the financial statements døs not cover the management commentary, and we do not express
any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the management
commentary and, in doing so, consider whether the management commentary is materially inconsistent with
the financial statements or our knowledge obtained in the audit or otherwise appears to be materially
misstated.
Moreover, it is our responsibility to consider whether the management commentary provides the information
required by relevant law and regulations. Based on the work we have performed, we conclude that the management commentary is in accordance with
the financial statements and has been prepared in accordance with the requirements in the relevant law and regulations. We did not identify any material misstatement of the management commentary.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration